Switch to:
More From Other Websites
[$$] Drugmakers alarmed by Trump pricing threat Jan 14 2017
ALEXION 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and... Jan 13 2017
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Jan 13 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion... Jan 12 2017
Trump takes aim at pharma Jan 12 2017
Here Is Why Red-Hot Alexion Is Only Suitable for Risk Takers Now Jan 11 2017
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Jan 11 2017
JPMorgan Makes Big Changes to US Analyst Focus List for January Jan 11 2017
Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU Jan 11 2017
ALEXION PHARMACEUTICALS INC Financials Jan 10 2017
Alexion Seeks Expanded Use for Soliris in US and EU Jan 10 2017
Blog Coverage Alexion Pharma Applies for US and EU Marketing Approval of Refractory Generalized... Jan 10 2017
Mysterious $5 Billion Biotech Firm Moderna Lays Out Drug Pipeline Jan 09 2017
Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference Jan 09 2017
Alexion Blood Disorder Meds Wins Orphan Drug Status Jan 09 2017
Alexion CEO: 'We're moving on' from shakeup Jan 09 2017
Bullish and Bearish Reversals in the Market Jan 09 2017
Lawsuit for Investors in Shares of Alexion Pharmaceuticals, Inc. (ALXN) Announced by Shareholders... Jan 09 2017
Alexion Blood Disorder Drug Gets Orphan Designation in U.S. Jan 09 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK